Please provide your email address to receive an email when new articles are posted on . Premenopausal women with higher endogenous estradiol levels have a lower risk for developing type 2 diabetes in ...

Please provide your email address to receive an email when new articles are posted on . Premenopausal bilateral oophorectomy before age 46 years raised odds of arthritis, asthma, bone fractures and ...

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had ...

Higher-income countries are seeing their rates of premenopausal breast cancer increase faster, whereas cases of postmenopausal breast cancer are increasing in number faster in lower-income studies.

SEATTLE -- The monoclonal antibody romosozumab (Evenity) increased bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis, according to a small, phase II open-label study.

Obesity may lead to a decline in lung function in premenopausal and postmenopausal women. ScienceDaily. Retrieved March 9, 2026 from www.sciencedaily.com / releases / 2022 / 02 / 220223094319.htm The ...

Osteoporosis, a disease which leads to bone fragility and an increased risk of fractures, is very common among postmenopausal women, affecting around one in three over the age of 50 worldwide. However ...

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...

or on the link below. More than 90% of women with newly diagnosed breast cancer present with stage I to III disease and, with optimal multidisciplinary therapy, are likely to survive their disease. Of ...

Systemic therapy for premenopausal women with hormone receptor–positive breast cancer has evolved in the last 5 years, but critical questions remain. Recent randomized trials have demonstrated a ...

The US Food and Drug Administration (FDA) today approved bremelanotide (Vyleesi, AMAG Pharmaceuticals), a first-in-class melanocortin 4 receptor agonist for hypoactive sexual desire disorder (HSDD) in ...

New research demonstrates that a CDK4/6 inhibitor, used in combination with standard endocrine therapy with temporary ovarian suppression significantly improves progression-free survival in younger ...